https://mindmedicinelaw.com/briefing/prior-psychedelic-use-and-diagnosis-predict-support-for-pat-small-survey-insight-20261103-56449The Psychedelic Journalen2026-11-04T22:10:11.782717+00:00Prior Psychedelic Use and Diagnosis Predict Support for PAT: Small Survey Insightspsychedelic-assisted therapy, public attitudes, mental health diagnosis, prior psychedelic use, survey research, policy implications, clinical adoption, self-reported data, legalization supporthttps://mindmedicinelaw.com/briefing/esketamine-in-depression-real-world-outcomes-vs-clinical-trials-20261103-56492The Psychedelic Journalen2026-11-04T22:09:25.547172+00:00Esketamine in Depression: Real-World Outcomes vs. Clinical Trialsesketamine, treatment-resistant depression, real-world evidence, clinical trials, methodological bias, placebo response, psychiatric policy, comparative effectiveness, FDA approval, pragmatic trialshttps://mindmedicinelaw.com/briefing/cardiac-risk-pathways-in-bav-cannabis-tryptamines-neuroplastogens-20261103-56508The Psychedelic Journalen2026-11-04T22:09:06.308468+00:00Cardiac Risk Pathways in BAV: Cannabis, Tryptamines, Neuroplastogensbicuspid aortic valve, cannabis cardiac risk, tryptamines safety, neuroplastogen analogs, pharmacogenomics, psychedelic clinical trials, 5-HT2B receptor, TGFB1 variant, NOS3 polymorphism, registry validationhttps://mindmedicinelaw.com/briefing/unified-theory-dmt-and-ketamine-anesthesia-via-sigma-1-entropy-and-overload-20261103-56509The Psychedelic Journalen2026-11-04T22:08:48.037598+00:00Unified Theory: DMT and Ketamine Anesthesia via Sigma-1, Entropy, and Overloaddmt anesthesia, ketamine mechanism, sigma-1 receptor, cortical entropy, dissociative overload, global neuronal workspace, anesthesia taxonomy, non-gabaergic anesthetics, clinical trial design, psychedelic neurosciencehttps://mindmedicinelaw.com/briefing/authority-level-priors-and-identity-implications-for-psychedelic-mechanisms-20261102-56486The Psychedelic Journalen2026-11-04T22:10:52.528167+00:00Authority-Level Priors and Identity: Implications for Psychedelic Mechanismsauthority-level priors, predictive processing, psychedelic therapy, identity-level beliefs, stress reactivity, clinical trial design, computational psychiatry, regulatory mechanisms, neurobiology of self, active inferencehttps://mindmedicinelaw.com/briefing/illicit-drug-marketing-on-thai-social-media-netnography-insights-for-policy-20261102-56511The Psychedelic Journalen2026-11-04T22:10:31.044959+00:00Illicit Drug Marketing on Thai Social Media: Netnography Insights for Policyillicit drug marketing, social media, thailand, netnography, coded language, cross-platform strategies, new psychoactive substances, digital surveillance, drug policy, harm reductionhttps://mindmedicinelaw.com/briefing/ai-driven-ligand-discovery-for-5-ht2a-new-paths-in-psychedelic-drug-design-20261102-56487The Psychedelic Journalen2026-11-04T22:09:57.922885+00:00AI-Driven Ligand Discovery for 5-HT2A: New Paths in Psychedelic Drug Designai drug design, 5-ht2a receptor, psychedelic research, ligand discovery, generative chemistry, central nervous system drugs, agonist antagonist, machine learning pharmacology, drug discovery workflowhttps://mindmedicinelaw.com/briefing/inmt-enzyme-localization-near-golgi-sheds-light-on-endogenous-dmt-in-human-brain-20261102-56450The Psychedelic Journalen2026-11-04T22:09:41.652444+00:00INMT Enzyme Localization Near Golgi Sheds Light on Endogenous DMT in Human Brainendogenous dmt, inmt enzyme, golgi apparatus, human neurons, psychedelic neuroscience, clinical research, psychiatric therapeutics, biomarker development, mechanism of actionhttps://mindmedicinelaw.com/briefing/multi-lab-mouse-study-challenges-persistent-psilocybin-effects-20261102-56469The Psychedelic Journalen2026-11-04T22:08:29.500172+00:00Multi-Lab Mouse Study Challenges Persistent Psilocybin Effectspsilocybin, mouse behavior, multi-institutional study, preclinical research, reproducibility, psychedelic science, translational research, regulatory policy, clinical trial designhttps://mindmedicinelaw.com/briefing/systematic-review-reveals-major-gaps-in-pap-implementation-research-20261102-56182The Psychedelic Journalen2026-11-03T22:06:41.129390+00:00Systematic Review Reveals Major Gaps in PAP Implementation Researchpsychedelic-assisted psychotherapy, implementation science, systematic review, clinical practice, mental health policy, regulatory compliance, public health, training models, access barriershttps://mindmedicinelaw.com/briefing/blood-pressure-risks-of-ketamine-esketamine-in-depression-systematic-review-prot-20261102-56227The Psychedelic Journalen2026-11-03T22:06:22.835591+00:00Blood Pressure Risks of Ketamine/Esketamine in Depression: Systematic Review Protocol (Global, 2026)ketamine, esketamine, blood pressure, hypertension risk, systematic review, depression treatment, clinical trials, regulatory guidance, cardiovascular safetyhttps://mindmedicinelaw.com/briefing/ketamine-s-neural-effects-on-working-memory-in-trd-fmri-evidence-and-implication-20261101-56500The Psychedelic Journalen2026-11-04T22:11:08.794963+00:00Ketamine’s Neural Effects on Working Memory in TRD: fMRI Evidence and Implicationsketamine, treatment-resistant depression, working memory, fMRI, neural circuits, clinical trial design, cognitive safety, regulatory implications, mechanistic researchhttps://mindmedicinelaw.com/briefing/spiritual-experiences-in-interoceptive-training-for-moud-clinical-implications-20261029-56222The Psychedelic Journalen2026-11-03T22:07:12.709479+00:00Spiritual Experiences in Interoceptive Training for MOUD: Clinical Implicationsinteroceptive awareness, spiritual experience, opioid use disorder, MOUD, mindful awareness in body-oriented therapy, substance use disorder, psychedelic-assisted therapy, adjunctive therapies, clinical researchhttps://mindmedicinelaw.com/briefing/ketamine-s-neuroprotection-in-parkinson-s-models-bdnf-independence-20261029-56233The Psychedelic Journalen2026-11-03T22:06:55.459219+00:00Ketamine’s Neuroprotection in Parkinson’s Models: BDNF Independenceketamine, parkinson's disease, neuroprotection, bdnf, trkB signaling, preclinical research, rodent models, mechanisms of action, clinical translation, neurodegenerative disease